RecruitingArrhythmogenic CardiomyopathyPKP2-ACMPKP2-ARVC
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
Eligible age
18–65 yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.
Sponsor: Lexeo Therapeutics
You may qualify if…
- ✓ Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)
- ✓ Documentation of a pathogenic or likely pathogenic truncating variant in PKP2
- ✓ Frequent premature ventricular contractions (PVCs)
- ✓ Patients must have an ICD placed prior to enrollment
- ✓ Left ventricular ejection fraction (LVEF) ≥ 50% for Part A participants. Left ventricular ejection fraction (LVEF) ≥40% for Part B participants.
You may not qualify if…
- ✕ Evidence of variant(s) in addition to PKP2 that meet standard criteria to be considered pathogenic or likely pathogenic for an arrhythmogenic cardiomyopathy.
- ✕ A history of other cardiac abnormalities as specified in the protocol.
- ✕ New York Heart Association symptoms of heart failure of Class IV at the time of consent.
- ✕ A history of prior gene transfer therapy.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06976606 · last updated 2025-05-16